- Wendy Arnone brings extensive executive leadership from the health insurance industry, complemented by a clinical background, to the CMTA Board of Directors
- Wendy's dedication to advancing healthcare, combined with her passion for improving patient outcomes, strengthens the CMTA's leadership in driving progress and fostering hope within the CMT community
GLENOLDEN, PA / ACCESSWIRE / April 22, 2024 / The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of health insurance industry veteran, Wendy Arnone, to its Board of Directors.
Wendy is a highly experienced executive with a clinical background, and has held leadership roles within insurance providers including UnitedHealthcare, Excellus BlueCross BlueShield, and HealthNow New York Inc. Wendy most recently served as West Region CEO for UnitedHealthcare's Individual and Employer business, a $10 billion region encompassing 13 states with over three million members. She brings an incredible wealth of healthcare industry expertise to the CMTA Board of Directors, along with significant leadership experience and financial acumen.
"It is a true honor to join the esteemed Board of Directors at the CMTA, an organization that embodies a never-ending dedication to accelerating research and providing support for those affected by CMT," said Wendy. "My journey with CMT spans over three decades, diagnosed at a time when research and resources were scarce. Through the remarkable work of the CMTA, I have witnessed firsthand the transformative impact of their initiatives on individuals living with this condition, including myself. I am deeply inspired by the opportunity to contribute my expertise from the healthcare industry towards driving progress and fostering hope for a brighter future. Together, we will continue to champion innovation, awareness, and ultimately, a world free of CMT."
"We are excited to welcome Wendy Arnone to the CMTA Board of Directors," said Gilles Bouchard, CMTA Chairman of the Board. "The depth and breadth of her executive experience in healthcare, combined with her passion for helping patients, will be invaluable as we continue our drive to achieve our vision of a world without CMT."
About CMT
Named after the three doctors who first described it in 1886: Charcot, Marie, and Tooth, CMT affects one in every 2,500 people-a rare disease subdivided into multiple subtypes, each with a lower prevalence. Due to the degradation of their nerves, people with CMT suffer lifelong progressive muscle weakness and atrophy of the arms and legs, and can affect other parts of the body. This leads to problems with balance, walking, hand use, and more. There currently is no treatment or cure for this debilitating disease.
About the CMTA
The CMTA is a community-led, community-driven 501(c)(3) nonprofit organization with a mission to support the development of new treatments for CMT, to improve the quality of life for people with CMT, and, ultimately, to find a cure. As the leading global philanthropic funder of CMT research, the CMTA unites the community with clinicians and industry experts to accelerate the advancement of treatments, with investments of more than $24 million since 2008. For more information, visit https://www.cmtausa.org
Contact Information
Kenny Raymond
Head of Communications, Charcot-Marie-Tooth Association
[email protected]
+1-734-862-8702
SOURCE: The Charcot-Marie-Tooth Association
View the original press release on newswire.com.